191 related articles for article (PubMed ID: 34534227)
1. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease.
Karmi N; Bangma A; Spekhorst LM; van Dullemen HM; Visschedijk MC; Dijkstra G; Weersma RK; Voskuil MD; Festen EAM
PLoS One; 2021; 16(9):e0256860. PubMed ID: 34534227
[TBL] [Abstract][Full Text] [Related]
2. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
3. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
4. Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways.
Luther J; Gala M; Patel SJ; Dave M; Borren N; Xavier RJ; Ananthakrishnan AN
Dig Dis Sci; 2018 Mar; 63(3):738-745. PubMed ID: 29372477
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
6. A
Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
[TBL] [Abstract][Full Text] [Related]
7. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
8. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
9. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.
Bastida G; Marín-Jiménez I; Forés A; García-Planella E; Argüelles-Arias F; Tagarro I; Fernandez-Nistal A; Montoto C; Aparicio J; Aguas M; Santos-Fernández J; Boscá-Watts MM; Ferreiro-Iglesias R; Merino O; Aldeguer X; Cortés X; Sicilia B; Mesonero F; Barreiro-de Acosta M
Dig Liver Dis; 2022 Jan; 54(1):76-83. PubMed ID: 34244110
[TBL] [Abstract][Full Text] [Related]
12. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
13. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
[TBL] [Abstract][Full Text] [Related]
14. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V
Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
[TBL] [Abstract][Full Text] [Related]
17. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
18. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.
Bravo F; Macpherson JA; Slack E; Patuto N; Cahenzli J; McCoy KD; Macpherson AJ; Juillerat P;
Clin Transl Gastroenterol; 2021 Feb; 12(2):e00298. PubMed ID: 33735154
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
Aliment Pharmacol Ther; 2019 Aug; 50(3):289-294. PubMed ID: 31267570
[TBL] [Abstract][Full Text] [Related]
20. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
